Depomed cutting one-fourth of staff

Menlo Park-based pharmaceutical firm Depomed Inc. (DEPO), is making staff cuts affecting approximately one-fourth of its staff following disappointing results in a phase 3 study in postherpetic neuralgia.

The company has two products on the market and other candidates in its development pipelines and holds proprietary drug delivery technology for the improvement of oral medications.

businessBusiness & Real Estate

If you find our journalism valuable and relevant, please consider joining our Examiner membership program.
Find out more at www.sfexaminer.com/join/

Just Posted

Man suing SFPD alleging officers beat him with batons

Cop attorney fires back: police were ‘interrupting a dangerous domestic violence incident’

Nuru corruption scandal prompts call to boost Ethics Commission budget

Watchdog agency lacks staff, resources to carry out its duties

Supes to boost subpoena power

Peskin legislation would allow committee to compel testimony under oath

Drug overdose deaths surpass 300 in San Francisco

Three-year rise in fatalities ‘generally driven by fentanyl’

Preston finds support for District 5 navigation center at community meeting

Supervisor hopes to narrow down list of possible locations within months

Most Read